Two groups of patients diagnosed with Myofascial Pain Dysfunction Syndrome (MPDS) will be included in this study. One group will receive trigger point injections of lidocaine alone. The other group will receive trigger point injections of lidocaine combined with magnesium sulfate. The study aims to compare the effectiveness of both treatments in reducing pain and improving muscle function. Patients will be assessed using a pain scale (VAS) and surface electromyography (sEMG) to measure muscle activity.
Age between 18 and 70 years.
Clinical diagnosis of Myofascial Pain Dysfunction Syndrome (MPDS).
Presence of active myofascial trigger points in accessible muscles (e.g., masseter, temporalis, upper trapezius).
Pain duration ≥ 3 months.
Known allergy or hypersensitivity to Lidocaine, Magnesium Sulfate, or related agents.
Current use of anticoagulants or history of bleeding disorders.
Systemic or local infection at or near the injection site.
History of fibromyalgia, central pain syndromes, or cancer-related pain.